" class="no-js "lang="en-US"> Aman Kant - Medtech Alert
Friday, April 12, 2024
Aman Kant

Aman Kant

About Aman Kant

I’ve spent the last 15 years driving pharmaceutical innovation through the development and application of disruptive technology-enabled tools. My career has focused on growth-hacking in start-up eco-systems, from scaling small business to accessing public markets.As Chief Business Officer, I drive all business aspects for the company’s continuous evolution, including:

• Driving business portfolio strategy encompassing commercial & clinical development, and management of CDMO & CRO partners
• Developing partnering strategy, overseeing collaborations & alliances, in/out licensing
• Engaging & onboarding key opinion leaders for key advisory roles
• Nurturing investor relationships for public and private fundraising
• Aligning marketing & PR activities with strategic goals

As a part of the leadership team, contributing to the strategic development and shaping of InveniAI in applying AI tools for drug discovery and development has been a key focus area.

With extensive knowledge of the business intricacies across biopharmaceutical R&D I have facilitated significant deals and strategic partnerships for AI technology applications resulting in multi-million dollar revenue.

I am backed by a fantastic team that is highly skilled and is helping me take the organization to new heights.

Related Story

Sosei Heptares and InveniAI Enter a Multi-target AI-powered and GPCR-focused Drug Discovery Collaboration

July 6 2021

Sosei Group Corporation (“the Company”) (TSE: 4565), the world leader in GPCR-focused structure-based drug design and […]